Advaxis jumps as FDA green-lights prostate cancer trial

Ayala Pharmaceuticals

07/01/2020 13:44

** Cancer treatment developer's  ADVX.O  shares jump 35.5%
to $1.45 premarket; set for best day in a year
    ** Gets FDA clearance to begin an early stage trial of
ADXS-504, its experimental treatment for prostate cancer
 urn:newsml:reuters.com:*:nGNXDwzqY
    ** One of the top three most actively traded stocks across
exchanges before the opening bell
    ** Stock plunged 69.9% in 2019

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com;))